Business Wire (Free subscription) | 02/12/2008
ABANO TERME, Italy--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A. announces that the opposition they filed against European Patent EP 0466300 B1 to Genzyme Corporation (Cambridge, MA, USA) has been entirely successful.
Business Wire (Free subscription) | 24/11/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has filed a supplemental New Drug Application with the U.S. Food and Drug Administration for the use of Clolar®
Business Wire (Free subscription) | 17/11/2008
CAMBRIDGE, Mass. & TRIESTE, Italy--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ), a global leader in biotechnology, and the International Center for Genetic Engineering and Biotechnology (ICGEB), a not-for-profit
Business Wire (Free subscription) | 13/11/2008
This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information....
EuroInvestor.co.uk (Free subscription) | 22/10/2008
Genzyme Corporation (NASDAQ: GENZ) announced today that third-quarter revenue rose 21 percent to $1.160 billion, compared with revenue of $960.2 million in the same period a year ago. .. - Read more
Business Wire (Free subscription) | 22/10/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) announced today that third-quarter revenue rose 21 percent to $1.160 billion, compared with revenue of $960.2 million in
Medical News Today (Free subscription) | 20/10/2008
Genzyme Corporation (Nasdaq: GENZ) today announced that its U.S. Biologic License Application (BLA) for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale will be discussed this Tuesday, October 21st, at a public meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee in Silver Spring, Maryland.
Allergic Info (Free subscription) | 27/11/2008
Researchers from Massachusetts General Hospital, contained via endorse at the cross of scientists from the Genzyme Corporation, own identified a soon-to-be awareness all for a hardened lung disease affecting hasty babe-in-arms. In a cram to show up in the American Journal of Physiology - Lung Cellular and Molecular Physiology, which have received early online secretion, the scientists...
The Earth Times Online Newspaper (Free subscription) | 26/11/2008
... designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Furthermore, Prochymal is being developed for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type...
Business Wire (Free subscription) | 26/11/2008
... designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Furthermore, Prochymal is being developed for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type...
Medical News Today (Free subscription) | 25/11/2008
Genzyme Corporation (Nasdaq: GENZ) announced today that it has filed a supplemental New Drug Application with the U.S. Food and Drug Administration for the use of Clolar® (clofarabine) to treat adult patients with acute myeloid leukemia (AML). The company has requested priority review of its application and, if granted, Clolar could be approved for this indication in the first half of...
PR News Wire (Free subscription) | 25/11/2008
... I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently...
PR News Wire (Free subscription) | 21/11/2008
... I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical...
Business Wire (Free subscription) | 17/11/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale for the
Red Orbit (Free subscription) | 07/11/2008
... designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Furthermore, Prochymal is being developed for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type...
